Mirabegron has been administered to healthy volunteers at single doses up to 400 mg. At this dose, adverse events reported included palpitations (1 of 6 subjects) and increased pulse rate exceeding 100 bpm (3 of 6 subjects). Multiple doses of mirabegron up to 300 mg daily for 10 days showed increases in pulse rate and systolic blood pressure when administered to healthy volunteers. Treatment for overdosage should be symptomatic and supportive. In the event of overdosage, pulse rate, blood pressure and ECG monitoring is recommended.
MYRBETRIQ® is contraindicated in patients who have known hypersensitivity reactions to mirabegron or any component of the tablet [see ADVERSE REACTIONS].
Last reviewed on RxList: 8/27/2015
This monograph has been modified to include the generic and brand name in many instances.
Additional Myrbetriq Information
Report Problems to the Food and Drug Administration
Find out what women really need.